Protalix Biotherapeutics (PLX) Stock Price, Quote & News

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 696 9345

Website: www.protalix.com

Address:

2 University Plaza, Suite 100, Hackensack, United States

NNINVEST May. 13 at 12:04 PM

$PLX Will anyone ask for FDA timeline and milestone related?

0 · Reply

StocktwitsEarnings May. 13 at 12:01 PM

$PLX Q1 '26 Earnings Results & Recap Protalix BioTherapeutics reported Q1 2026 net income of $18.32M, up from a -$3.62M net loss in Q1 2025, driven by total revenue increasing to $33.75M from $10.11M.

0 · Reply

CliffordCapital May. 13 at 11:28 AM

$PLX just imagine we didn’t get that E4W approval - we would be sitting at -7M netloss and depleting cash :D they would need to go for dilution or debt again :D atleast we are safe from a cf point of view. Only thing that annoys me is that chiesi sales are so sloooow… I was hoping for higher numbers and increased guidance

1 · Reply

brunoq14 May. 13 at 11:28 AM

$PLX According to Secarna's website, the average "Discovery" period for their collaborators is six to twelve months. It's been about four months so far for Protalix. If they move on to a more focused stage, that could be a catalyst.

0 · Reply

CliffordCapital May. 13 at 11:22 AM

$PLX earnings were super mediocre. Doesn‘t change the fact that this is criminally undervalued. 😂 that’s probably why it’s up PM. We have 50M cash and 50M sales (growing) and P2 readout next year. All this for 150M MC is ridiculous.

0 · Reply

brunoq14 May. 13 at 11:21 AM

$PLX Well, presumably Schwab knew about the milestone payment, and they nevertheless predicted a loss of nine cents for the quarter. Turns out we made twenty-two cents.

0 · Reply

CliffordCapital May. 13 at 11:20 AM

$PLX they forecast 30M + elfabrio sales for 26. every quarter should be 10M + elfabrio from now on. 😂😂 I

0 · Reply

PickStocker May. 13 at 11:19 AM

$PLX Q1 2025 Chiesi product sales: $0 Q1 2026 Chiesi product sales: $3.5M Small change, but in the right direction.

1 · Reply

brunoq14 May. 13 at 11:17 AM

$PLX There was not one word about seeking a similar dosing change from the FDA.

0 · Reply

ToRni27 May. 13 at 11:16 AM

$PLX I hope brainless algos will trade this up and may we can sell 10-15% of our holdings to buyback later 😂 I got more thsn another to wallpaper my complete house. 🙈

0 · Reply

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 6, 2026, 6:50 AM EDT - 7 days ago

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 6:50 AM EDT - 2 months ago

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Mar 11, 2026, 6:50 AM EDT - 2 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

2026-03-09T10:16:17.000Z - 2 months ago

Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

Mar 9, 2026, 6:00 AM EDT - 2 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

2026-01-30T14:56:18.000Z - 3 months ago

Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing

Jan 30, 2026, 9:47 AM EST - 3 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Jan 30, 2026, 9:47 AM EST - 3 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Jan 5, 2026, 6:50 AM EST - 4 months ago

Protalix BioTherapeutics Letter to Stockholders

2025-12-17T12:02:15.000Z - 5 months ago

Protalix, Secarna Pharmaceuticals enter collaboration and option agreement

Dec 17, 2025, 6:50 AM EST - 5 months ago

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

2025-11-21T11:10:30.000Z - 6 months ago

Protalix price target lowered to $12 from $15 at H.C. Wainwright

Nov 13, 2025, 8:00 AM EST - 6 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 6:50 AM EST - 6 months ago

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Nov 6, 2025, 6:50 AM EST - 6 months ago

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Nov 3, 2025, 4:30 PM EST - 6 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

2025-10-17T11:11:05.000Z - 7 months ago

Protalix, Chiesi Global: CHMP issues negative opinion for Elfabrio

Oct 17, 2025, 6:58 AM EDT - 7 months ago

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Sep 16, 2025, 10:30 AM EDT - 8 months ago

Protalix BioTherapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 11, 2025, 10:55 AM EDT - 8 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 2, 2025, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Aug 7, 2025, 12:53 PM EDT - 9 months ago

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

2025-07-21T10:55:33.000Z - 10 months ago

Protalix appoints Gilad Mamlok as CFO

Jul 21, 2025, 6:50 AM EDT - 10 months ago

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

2025-06-30T14:45:15.000Z - 11 months ago

Protalix added to Russell 3000, Russell 2000 Indexes

Jun 30, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

May 20, 2025, 4:30 PM EDT - 1 year ago

Protalix BioTherapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 5, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

2025-04-28T21:05:49.000Z - 1 year ago

Protalix files $100M mixed securities shelf

Mar 24, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

2025-03-20T01:55:45.000Z - 1 year ago

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2024

Mar 17, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Mar 10, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Feb 4, 2025, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

2025-02-03T11:15:19.000Z - 1 year ago

Protalix price target raised to $15 from $10 at H.C. Wainwright

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

2024-12-09T12:12:11.000Z - 1 year ago

Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission

Dec 9, 2024, 6:30 AM EST - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 1 year ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Transcript: Investor Day 2024

Jun 13, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2024

2024-05-10T11:05:18.000Z - 2 years ago

Options Volatility and Implied Earnings Moves Today, May 10, 2024

AQN CBAT DOCN ENB HMC MITK NVAX

May 10, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

May 3, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Dec 26, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2023

Nov 6, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Oct 30, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

NNINVEST May. 13 at 12:04 PM

$PLX Will anyone ask for FDA timeline and milestone related?

0 · Reply

StocktwitsEarnings May. 13 at 12:01 PM

0 · Reply

CliffordCapital May. 13 at 11:28 AM

1 · Reply

brunoq14 May. 13 at 11:28 AM

0 · Reply

CliffordCapital May. 13 at 11:22 AM

0 · Reply

brunoq14 May. 13 at 11:21 AM

$PLX Well, presumably Schwab knew about the milestone payment, and they nevertheless predicted a loss of nine cents for the quarter. Turns out we made twenty-two cents.

0 · Reply

CliffordCapital May. 13 at 11:20 AM

$PLX they forecast 30M + elfabrio sales for 26. every quarter should be 10M + elfabrio from now on. 😂😂 I

0 · Reply

PickStocker May. 13 at 11:19 AM

$PLX Q1 2025 Chiesi product sales: $0 Q1 2026 Chiesi product sales: $3.5M Small change, but in the right direction.

1 · Reply

brunoq14 May. 13 at 11:17 AM

$PLX There was not one word about seeking a similar dosing change from the FDA.

0 · Reply

ToRni27 May. 13 at 11:16 AM

$PLX I hope brainless algos will trade this up and may we can sell 10-15% of our holdings to buyback later 😂 I got more thsn another to wallpaper my complete house. 🙈

0 · Reply

LQQKER_INSIDER May. 13 at 11:13 AM

$PLX 💪🏻💪🏻 But it's pumping in the pre-market !!!

0 · Reply

ToRni27 May. 13 at 11:11 AM

$PLX we are cooked. The drug is not selling well. 4 week dosing will change that but that needs time like a year.

0 · Reply

ToRni27 May. 13 at 11:09 AM

$PLX so Q2 needs to offer product sales of 18M+. Lets hope 🙈

0 · Reply

ToRni27 May. 13 at 11:08 AM

$PLX diluted shares: 83M. They added 2.5M shares. Omfg.

0 · Reply

ElZocko2 May. 13 at 11:08 AM

$PLX exactly. the same we have experienced the other way as well. so lets hype that GREAT stock a bit :D BUY BUY BUY

0 · Reply

TiTb May. 13 at 11:07 AM

$PLX welp.... For better or worse..... Until mid 27 nothing to look for . Hope they will stay and achieve their estimated sales declared amd reaffirmed. All the rest loke SP for now are jusr background noise Luck 🤞 Success

0 · Reply

PickStocker May. 13 at 11:06 AM

$PLX My guess is that Mr. Market only cares about the EPS. Let's see.

1 · Reply

ElZocko2 May. 13 at 11:04 AM

$PLX up 10% in PM and in Germany.

1 · Reply

ToRni27 May. 13 at 11:03 AM

$PLX 7.4M in revenues OMFG red flag. We thought Q4 was bad. Lol

0 · Reply

CliffordCapital May. 13 at 11:02 AM

$PLX 3.5$ Elfabrio and elelyso declining already. 🥶 🥶 without the milestone we would be sitting at a 6.5M net loss. 😤 atleast they reaffirmed guidance…

0 · Reply

LQQKER_INSIDER May. 13 at 11:01 AM

$PLX

0 · Reply

ElZocko2 May. 13 at 11:00 AM

$PLX we only can hope algos and traders buying this up today due to the great eps triggered by the milestone. for everyone involved longer, another disappointment

0 · Reply

Market Cap	156.31M
Revenue (ttm)	52.74M
Net Income (ttm)	-6.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	9.02
Profit Margin	-12.51%
Debt to Equity Ratio	0.00

Volume	590,900
Avg Vol	855,230
Day's Range	N/A - N/A
Shares Out	80.57M
Stochastic %K	10%
Beta	-0.01
Analysts	Strong Sell
Price Target	$11.00